BHL-I could bind to the two target antigens with high activity and specificity, and could bridge human ovarian carcinoma cell line SKOV3 cell and human T cell line Jurkat expressing CD3-antigen on surface together as demonstrated by ELISA and FACS. Western blotting showed the specific expression of the tumor-associated antigen.